Tommy B. Andersson

9.5k citations

119 papers · 7.1k indexed · 1 hit paper · h-index 48

Pharmacology top 0.02%
Oncology top 1%
Molecular Biology top 5%
Surgery top 5%
Hepatology top 0.5%

Co-authors: Kajsa P. Kanebratt Xueqing Li Magnus Ingelman‐Sundberg Collen Masimirembwa Lars Weidolf Marianne Ridderström Inger Johansson Charlotta Otter
Topics: Pharmacogenetics and Drug Metabolism (79 papers)Drug Transport and Resistance Mechanisms (55 papers)Drug-Induced Hepatotoxicity and Protection (24 papers)
Cited by: Pharmacology Hepatology Oncology
Journals: Journal of Biological Chemistry Hepatology Scientific Reports
Partner nations: Sweden United Kingdom United States

In The Last Decade

Tommy B. Andersson

117 papers receiving 6.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

COMPARISON OF INHIBITORY EFFECTS OF THE PROTON PUMP-INHIBITING DRUGS OMEPRAZOLE, ESOMEPRAZOLE, LANSOPRAZOLE, PANTOPRAZOLE, AND RABEPRAZOLE ON HUMAN CYTOCHROME P450 ACTIVITIES

2004 495 citations Xueqing Li, Tommy B. Andersson et al. Drug Metabolism and Disposition profile →

Peers

Countries citing papers authored by Tommy B. Andersson

Since Specialization

Citations

This map shows the geographic impact of Tommy B. Andersson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tommy B. Andersson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tommy B. Andersson more than expected).

Fields of papers citing papers by Tommy B. Andersson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tommy B. Andersson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tommy B. Andersson. The network helps show where Tommy B. Andersson may publish in the future.

Co-authorship network of co-authors of Tommy B. Andersson

This figure shows the co-authorship network connecting the top 25 collaborators of Tommy B. Andersson. A scholar is included among the top collaborators of Tommy B. Andersson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tommy B. Andersson. Tommy B. Andersson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	In Vitro Assessment of the Drug–Drug Interaction Potential of Verinurad and Its Metabolites as Substrates and Inhibitors of Metabolizing Enzymes and Drug Transporters 2021 ·Journal of Pharmacology and Experimental Therapeutics ·(unknown),Anna Vildhede,Tommy B. Andersson,Fredrik Erlandsson,Caroline A. Lee,Susanne Johansson,Constanze Hilgendorf	3
2	Correlation of Body Weight and Composition With Hepatic Activities of Cytochrome P450 Enzymes 2020 ·Journal of Pharmaceutical Sciences ·(unknown),(unknown),Ida Robertsen,Marianne Kristiansen Kringen,Maria Vistnes,Jøran Hjelmesæth,Rune Sandbu,Line Kristin Johnson,(unknown),Rasmus Jansson‐Löfmark,Cecilia Karlsson,Shalini Andersson,Anders Åsberg,Tommy B. Andersson,Hege Christensen	40
3	Protein quantification of human hepatic drug transporters and metabolizing enzymes: an inter-laboratory and methodological comparison 2016 ·Drug Metabolism Reviews ·Christine Wegler,Fabienne Z. Gaugaz,Tommy B. Andersson,Jacek R. Wiśniewski,Diana Busch,Stefan Oswald,F. T. Weiss,Helen Hammer,Thomas Joos,Oliver Poetz,Heleen M. Wortelboer,Evita van de Steeg,Brahim Achour,Amin Rostami,Per Artursson	1
4	Highly Synchronized Expression of Lineage‐Specific Genes during In Vitro Hepatic Differentiation of Human Pluripotent Stem Cell Lines 2016 ·Stem Cells International ·(unknown),Björn Olsson,Josefina Edsbagge,Barbara Küppers-Munther,(unknown),Annika Asplund,Tommy B. Andersson,Petter Björquist,Helena Carén,Stina Simonsson,Peter Sartipy,Jane Synnergren	13
5	Long-Term Chronic Toxicity Testing Using Human Pluripotent Stem Cell–Derived Hepatocytes 2014 ·Drug Metabolism and Disposition ·Gustav Holmgren,Anna-Karin Sjögren,Isabel Barragán,Alan Sabirsh,Peter Sartipy,Jane Synnergren,Petter Björquist,Magnus Ingelman‐Sundberg,Tommy B. Andersson,Josefina Edsbagge	76
6	Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells 2013 ·Biochemical Pharmacology ·(unknown),Pär Nordell,Annika Asplund,(unknown),(unknown),Gustav Holmgren,L. S. P. Davidson,Gabriella Brolén,Josefina Edsbagge,Petter Björquist,Barbara Küppers-Munther,Tommy B. Andersson	77
7	An Ex Vivo Perfusion System Emulating In Vivo Conditions in Noncirrhotic and Cirrhotic Human Liver 2012 ·Journal of Pharmacology and Experimental Therapeutics ·Thomas Schreiter,G. Marquitan,Malin Darnell,Jan‐Peter Sowa,Martina Bröcker‐Preuß,Tommy B. Andersson,Hideo A. Baba,Marcus Furch,Gavin E. Arteel,Zoltán Máthé,Jürgen Treckmann,Guido Gerken,Robert K. Gieseler,Ali Canbay	5
8	Impact of OATP1B1, MDR1, and CYP3A4 Expression in Liver and Intestine on Interpatient Pharmacokinetic Variability of Atorvastatin in Obese Subjects 2012 ·Clinical Pharmacology & Therapeutics ·(unknown),(unknown),Gunn Signe Jakobsen,Sara Bremer,Espen Molden,Anders Åsberg,Jøran Hjelmesæth,Tommy B. Andersson,Rune Sandbu,Hege Christensen	86
9	Scaling Down of a Clinical Three-Dimensional Perfusion Multicompartment Hollow Fiber Liver Bioreactor Developed for Extracorporeal Liver Support to an Analytical Scale Device Useful for Hepatic Pharmacological In Vitro Studies 2011 ·Tissue Engineering Part C Methods ·Katrin Zeilinger,Thomas Schreiter,Malin Darnell,Therése Söderdahl,Marc Lübberstedt,(unknown),Daniel Knobeloch,Andreas K. Nüssler,Jörg C. Gerlach,Tommy B. Andersson	88
10	Hepatic Disposition of Ximelagatran and Its Metabolites in Pig; Prediction of the Impact of Membrane Transporters Through a Simple Disposition Model 2010 ·Pharmaceutical Research ·Erik Sjögren,Ulf Bredberg,(unknown),Björn Arvidsson,Jonas Bergquist,Tommy B. Andersson,Hans Lennernäs	3
11	4β‐Hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half‐life of elimination after induction with rifampicin 2008 ·British Journal of Clinical Pharmacology ·Ulf Diczfalusy,Kajsa P. Kanebratt,Eva Bredberg,Tommy B. Andersson,Ylva Böttiger,Leif Bertilsson	107
12	HepaRG Cells as an in Vitro Model for Evaluation of Cytochrome P450 Induction in Humans 2007 ·Drug Metabolism and Disposition ·Kajsa P. Kanebratt,Tommy B. Andersson	162
13	Prediction of drug-induced liver injury in humans by using in vitro methods: The case of ximelagatran 2007 ·Toxicology in Vitro ·Kerstin Kenne,Inger Skånberg,Björn Glinghammar,Alain Berson,Dominique Pessayre,Jean-Pierre Flinois,Philippe Beaune,(unknown),(unknown),Stefan Carlsson,Tommy B. Andersson	35
14	CHARACTERIZATION AND PARTIAL PURIFICATION OF THE RAT AND HUMAN ENZYME SYSTEMS ACTIVE IN THE REDUCTION OF N-HYDROXYMELAGATRAN AND BENZAMIDOXIME 2005 ·Drug Metabolism and Disposition ·(unknown),Yvonne Hofmann,Åsa Nordling,Xueqing Li,(unknown),Tommy B. Andersson,Magnus Ingelman‐Sundberg,Inger Johansson	31
15	COMPARISON OF INHIBITORY EFFECTS OF THE PROTON PUMP-INHIBITING DRUGS OMEPRAZOLE, ESOMEPRAZOLE, LANSOPRAZOLE, PANTOPRAZOLE, AND RABEPRAZOLE ON HUMAN CYTOCHROME P450 ACTIVITIESbreakdown → 2004 ·Drug Metabolism and Disposition ·Xueqing Li,Tommy B. Andersson,(unknown),Lars Weidolf	495
16	AN EVALUATION OF THE IN VITRO METABOLISM DATA FOR PREDICTING THE CLEARANCE AND DRUG-DRUG INTERACTION POTENTIAL OF CYP2C9 SUBSTRATES 2004 ·Drug Metabolism and Disposition ·Tommy B. Andersson,Eva Bredberg,Hans Ericsson,(unknown)	56
17	Ximelagatran, an Oral Direct Thrombin Inhibitor, Has a Low Potential for Cytochrome P450-Mediated Drug-Drug Interactions 2003 ·Clinical Pharmacokinetics ·Eva Bredberg,Tommy B. Andersson,Lars Frison,(unknown),Susanne Johansson,(unknown),Marita Larsson,Ulf G. Eriksson	83
18	Cytochrome P 450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells 2002 ·European Journal of Clinical Pharmacology ·Tashinga E. Bapiro,Tommy B. Andersson,Charlotta Otter,Julia A. Hasler,Collen Masimirembwa	24
19	Interindividual Differences in Hepatic Expression of CYP3A4: Relationship to Genetic Polymorphism in the 5′-Upstream Regulatory Region 1999 ·Biochemical and Biophysical Research Communications ·(unknown),Lena Löfberg,Niclas Tindberg,Tommy B. Andersson,Magnus Ingelman‐Sundberg	254
20	Phenobarbital Induction of Gene Expression in a Primary Culture of Rainbow Trout Hepatocytes 1996 ·Journal of Biological Chemistry ·Marianne D. Sadar,(unknown),(unknown),Per‐Erik Olsson,Tommy B. Andersson	48

About Tommy B. Andersson

Tommy B. Andersson is a scholar working on Pharmacology, Hepatology and Oncology, having authored 119 papers that have together received 7.1k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (79 papers), Drug Transport and Resistance Mechanisms (55 papers) and Drug-Induced Hepatotoxicity and Protection (24 papers). The work is most often cited by research in Pharmacology (3.1k citations), Hepatology (1.0k citations) and Oncology (1.9k citations). Tommy B. Andersson has collaborated with scholars based in Sweden, United Kingdom and United States. Frequent co-authors include Kajsa P. Kanebratt, Xueqing Li, Magnus Ingelman‐Sundberg, Collen Masimirembwa, Lars Weidolf, Marianne Ridderström, Inger Johansson, Charlotta Otter, Volker M. Lauschke and Catherine C. Bell. Their work appears in journals such as Journal of Biological Chemistry, Hepatology and Scientific Reports.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact